Skip to main content

Table 2 Clinicopathological information for patients in the METABRIC data set

From: Basal-like breast cancer: molecular profiles, clinical features and survival outcomes

 

Training set

Validation set

 

Basal I

Basal II

Basal I

Basal II

Age [years]

    

≤ 40

7

18

4

17

41 to 50

11

18

10

21

51 to 60

8

20

9

16

> 60

9

24

13

35

mean

50.6

52.5

54.7

54.1

p-value

0.46

0.8

MS

    

Pre/post

18/17

36/43

15/21

37/52

Pre/post (%)

51.4%

45.6%

41.7%

41.6%

p-value

0.31

1

Size [cm]

    

≤ 2 cm

15

30

17

32

> 2 cm

20

50

19

55

Mean

23.5

30.6

22.1

29.6

p-value

0.01

0.005

Grade

    

Grade 2

2

8

5

3

Grade 3

33

71

30

85

Na

0

1

1

1

Mean

2.9

2.9

2.9

3

p-value

0.4

0.092

NPI

    

≤2.4

0

1

1

1

2.4 to 3.4

1

6

3

2

3.4 to 5.4

28

62

27

77

>5.4

6

11

5

9

Mean

4.7

4.6

4.5

4.6

p-value

0.43

0.7

Lymph Node

    

Neg/pos

16/19

37/43

17/19

47/42

Neg/pos (%)

45.7%

46.2%

47.2%

52.8%

p-value

1

0.34

Histology

    

ILC

0

2

0

1

IDC

28

70

23

83

IDC-med

7

5

9

3

Others

0

3

4

2

p-value

0.001

5.4·10−8

p53

    

Mut/wild

1/15

11/14

2/11

12/17

Mut/wild (%)

6.25%

44%

15.4%

41.4%

p-value

1.1·10−7

7·10−4

Population size

    
 

35

80

36

89

  1. The clinicopathological features described are: Age in years, menopausal status (MS), tumour Size in cm, tumour Grade [1–3], Nottingham Prognostic Index (NPI), Lymph Node invasion, histopathological classification (Histology) and p53 status, for Basal I and II subgroups in the METABRIC discovery and validation sets. In all cases, the p-value indicates the significance of the difference between Basal I and II subgroups. For numerical variables (Age, Size, Grade, and NPI) it was calculated using the ANOVA on ranks; for the categorical (MS, Lymph Node, Histology, p53), a binomial test was used. Population sizes for each group are indicated in the last row. Tumour histology is as follows: IDC=Invasive Ductal Carcinoma, ILC=Invasive Lobular Carcinoma, IDC-med=Medullary Carcinoma, and others include tubular, mucinous and phyllodes tumours
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us